Must See: 'Under the Skin' - How Aluminum Compounds in HPV Vaccines Cause Injuries
August 5, 2022
"Under the Skin," a new documentary by science journalist Bert Ehgartner, explores research into the aluminum compounds used in vaccines, including a new "extra-strong" aluminum compound used in Merck's Gardasil vaccine for human papillomavirus.
A new documentary reveals how Merck's Gardasil, marketed as a vaccine to prevent cervical cancer, became a global blockbuster through an aggressive marketing campaign, despite rare — but serious — side effects that left girls injured and struggling for answers.
"Under the Skin," by science journalist Bert Ehgartner, explores research into the aluminum compounds — added "experimentally" to vaccines almost 100 years ago — and a new "extra-strong" aluminum compound, amorphous aluminum hydroxyphosphate sulfate (AAHS), used in the Gardasil vaccine for human papillomavirus (HPV).
According to the National Cancer Institute, HPV is a group of more than 200 related viruses, some of which are spread through vaginal, anal or oral sex. Sexually transmitted HPV types fall into two groups: low risk and high risk.
Low-risk HPVs rarely cause disease, while high-risk HPVs can cause several types of cancer, including cervical cancer.
The relationship between aluminum and side effects experienced by thousands of girls after receiving the HPV vaccine was ignored until a team of Danish doctors collected dozens of cases and sent a safety warning to the European Medicines Agency (EMA).
According to The BMJ, documentation from the Danish Medicines Agency shows discrepancies in trial documents of two Gardasil prelicensure clinical trials, one in 2002, and one in 2003.
For both trials, the EMA appears to have authorized potassium aluminum sulfate as the adjuvant and not AAHS.
In addition, the 2002 trial participants were told the comparator was saline, even though the comparator was AAHS in an expedient consisting of L-histidine, polysorbate-80, sodium borate and sodium chloride.
The EMA said AAHS was introduced without any prelicensure safety evaluation. However, the EMA and World Health Organization concluded "high vaccine safety and efficacy."
Merck describes Gardasil's AAHS adjuvant as physically and functionally distinct from all other previously used aluminum adjuvants. However, according to The BMJ, "There is a need for rigorous evaluation of the benefits and harms of the adjuvant AAHS."
Ehgartner told The Defender:
"Vaccine manufacturers are in a dilemma because it would cost hundreds of millions to test novel — less problematic — adjuvants. Therefore, they simply do nothing. And the drug authorities — which are financed to a large extent by the vaccine manufacturers — so far see no need to do so."
https://childrenshealthdefense.org/defender/under-the-skin-aluminum-hpv-vaccines-injuries/
Website: https://unterdiehaut.online/en/
